רמיפריל אינובמד 10 ישראל - עברית - Ministry of Health

רמיפריל אינובמד 10

inovamed ltd - ramipril - טבליה - ramipril 10 mg - ramipril

רמיפריל אינובמד 2.5 ישראל - עברית - Ministry of Health

רמיפריל אינובמד 2.5

inovamed ltd - ramipril - טבליה - ramipril 2.5 mg - ramipril

רמיפריל אינובמד 5 ישראל - עברית - Ministry of Health

רמיפריל אינובמד 5

inovamed ltd - ramipril - טבליה - ramipril 5 mg - ramipril

ביקאלוטמיד אינובמד 150 מג ישראל - עברית - Ministry of Health

ביקאלוטמיד אינובמד 150 מג

inovamed ltd - bicalutamide - טבליות מצופות פילם - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0), bicalutamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable

מונטהלוקאסט אינובמד 5 מ"ג ישראל - עברית - Ministry of Health

מונטהלוקאסט אינובמד 5 מ"ג

inovamed ltd - montelukast as sodium 5 mg - chewable tablets - montelukast - montelukast inovamed is indicated in pediatric patients 6 to 14 years of age for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction.montelukast inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 6 to 14 years of age.

מונטהלוקאסט אינובמד 4 מ"ג ישראל - עברית - Ministry of Health

מונטהלוקאסט אינובמד 4 מ"ג

inovamed ltd - montelukast as sodium 4 mg - chewable tablets - montelukast - montelukast inovamed is indicated in pediatric patients 2 to 5 years of age for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. montelukast inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 to 5 years of age.

מונטהלוקאסט אינובמד 10 מ"ג ישראל - עברית - Ministry of Health

מונטהלוקאסט אינובמד 10 מ"ג

inovamed ltd - montelukast as sodium 10 mg - film coated tablets - montelukast - montelukast inovamed is indicated in adult and adolescents 15 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction.montelukast inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and adolescents 15 years of age and older.

אונדנסטרון אינובמד להזרקה 2 מ"ג/מ"ל ישראל - עברית - Ministry of Health

אונדנסטרון אינובמד להזרקה 2 מ"ג/מ"ל

inovamed ltd - ondansetron as hydrochloride dihydrate 2 mg / 1 ml - solution for injection - ondansetron - adults:ondansetron inovamed is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. ondansetron inovamed is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:ondansetron inovamed is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.

אקסאמסטאן אינובמד ישראל - עברית - Ministry of Health

אקסאמסטאן אינובמד

inovamed ltd - exemestane 25 mg - film coated tablets - exemestane - exemestane inovamed is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane inovamed is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. exemestane inovamed is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

אונדנסטרון אינובמד 4 מג ישראל - עברית - Ministry of Health

אונדנסטרון אינובמד 4 מג

inovamed ltd - ondansetron as hydrochloride dihydrate - טבליות מצופות פילם - ondansetron as hydrochloride dihydrate 4 mg - ondansetron